Clinicopathologic features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma
American Journal of Clinical Pathology · 2024
DOI: 10.1093/ajcp/aqae012 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2024. Verfasst von Ziyuan Shen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China; Departments of. Hauptthemen laut MEDLINE: Ki-1 Antigen, Lymphoma, Extranodal NK-T-Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, Jiangsu Key Research and Development Project.
Abstract (Originalsprache)
Objectives
Previous studies have been inconsistent concerning the association between the prognostic value of CD30 expression and extranodal natural killer/T-cell lymphoma (ENKTL).
Methods
CD30 expression in 82 patients with newly diagnosed ENKTL (mean age, 50 years; 73.2% male) was assessed by immunohistochemistry on paraffin-embedded sections. The level of CD30 expression was categorized into negative (0%, no staining) and positive groups.
Results
Sixty-seven cases exhibited positive CD30 expression, and the main between-group difference was the Chinese Southwest Oncology Group and Asia Lymphoma Study Group (CA) ENKTL stage and Eastern Cooperative Oncology Group (ECOG) performance status. The cutoff point for CD30 expression was 40% by restricted cubic splines analysis. The overall survival of patients with high expression (>40%) was statistically superior to negative (0%) and low-expression groups. A positive correlation was observed between CD30 and Epstein-Barr virus–encoded small RNA status (r = 0.305). Multivariable analysis suggested that positive CD30 expression (hazard ratio, 0.420 [95% CI, 0.193-0.914]; P = .029) and CA advanced stage (hazard ratio, 2.844 [95% CI, 1.371-5.896]; P = .005) were independent prognostic factors for ENKTL.
Conclusions
Positive CD30 expression was a favorable prognostic factor for ENKTL, and CD30 expression could restratify the survival of patients in clinical subgroups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China; Departments of.
- Pathology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Department of Hematology, Linyi People's Hospital, Linyi, China.
- Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
- Key Laboratory of Bone Marrow Stem Cell, Xuzhou, China.
Förderung
- Natural Science Foundation of Jiangsu Province
- Jiangsu Key Research and Development Project
Zitieren
APA
Shen, Z., Wang, Y., Xie, R., Zhang, Q., Xing, X., Zhang, S., Liu, H., & Sang, W. (2024). Clinicopathologic features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae012
Vancouver
Shen Z, Wang Y, Xie R, Zhang Q, Xing X, Zhang S, et al. Clinicopathologic features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma. American Journal of Clinical Pathology. 2024. doi:10.1093/ajcp/aqae012
BibTeX
@article{Shen2024,
author = {Shen, Ziyuan and Wang, Yubo and Xie, Ruiyang and Zhang, Qing and Xing, Xing and Zhang, Shuo and Liu, Hui and Sang, Wei},
title = {Clinicopathologic features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma},
journal = {American Journal of Clinical Pathology},
year = {2024},
doi = {10.1093/ajcp/aqae012}
}
EUVIMED